Search results for: Oncology
Filter search results
Real Option Value and Path Dependence in Oncology Innovation
1 April 2014
…at launch. As the author points out, oncology drugs in particular often follow the… Based on an OHE Lunchtime Seminar, this publication addresses a persistent issue: how to adequately reward…
Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?
7 December 2023, 12:00am
…of the Immuno-Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies, including the European Society for Medical Oncology. Frederique has over 400 publications and…
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
…Scotland, products used in oncology and orphan disease were associated with a lower odds of receiving a positive HTA recommendation compared with non-oncology products and products which did not receive…
OHE Workshop: Surrogate Endpoints as Predictors of Overall Survival in Oncology
14 July 2016
On Tuesday 28th June 2016 OHE held a workshop on the topic of surrogate endpoints as predictors of overall survival in oncology. The workshop was commissioned by the Pharmaceutical Oncology…
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
…A., Lothgren, M., Steuten, L., and Bruce, A., 2021. Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology. OHE Consulting Report, London: Office of Health…
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
3 July 2018
…Summers, Y. and Devlin, N. 2018. Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology. OHE Consulting Report, London: Office of Health Economics. RePEc…
Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
1 December 2017
…and made mandatory for orphan and oncology medicines. We analysed routine funding in the NHS for new medicines recently authorised via the centralised procedure with a particular focus on oncology…
The Expanding Value Footprint of Oncology Treatments
13 May 2014
…A., 2014. The expanding value footprint of oncology treatments. Consulting report. London: Office of Health Economics. For additional information about this study and OHE Consulting, please contact Jorge Mestre-Ferrandiz. …
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
…K.K., Mestre-Ferrandiz, J., Towse, A. and Smyth, E.H. (2013) A review of health technology appraisals: Case studies in oncology. International Journal of Technology Assessment in Health Care. FirstView article. doi:10.1017/S0266462312000669. (subscription required)…